Drugs / imaradenant
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04478513 | Jul → Dec 2020 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03980821 | Jul 2019 → Sep 2020 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03710434 | Nov 2018 → Apr 2019 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02740985 | Jun 2016 → Dec 2020 | castration-resistant prostate carcinoma, colorectal carcinoma, high grade malignant neoplasm, non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03381274 | May 2018 → May 2021 overdue | non-small cell lung carcinoma | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04495179 | Aug 2020 → Nov 2021 | castration-resistant prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04089553 | Aug 2019 → Jun 2021 | castration-resistant prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | imaradenant | “Imaradenant is a novel potent and selective adenosine A2A receptor antagonist that is hypothesized to reduce immune suppression in the tumor microenvironment.” PMID 38086998 ↗ Dec 2023 |
| Known as | AZD-4635 (HTL1071) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594442 ↗ |
| Known as | AZD4635 | “Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.” PMID 38086998 ↗ Dec 2023 |
| Known as | HTL-1071 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594442 ↗ |
| Known as | IMARADENANT (AZD4635) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594442 ↗ |
| Action | Inhibit | “Adenosine A2a receptor antagonist” CHEMBL4594442 ↗ |
| Modality | Small molecule | — CHEMBL4594442 ↗ |
| Route | Oral | “AZD4635 will be administered orally as a nanosuspension or capsule” NCT02740985 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL4594442 ↗ |